The selective progesterone receptor modulator CDB4124 inhibits proliferation and induces apoptosis in uterine leiomyoma cells

Fertility and Sterility

Volumn 93, Issue 8, 2010, Pages 2668-2673

  Luo, Xia ^a,b   Yin, Ping ^a   Coon V , John S ^a   Cheng, You Hong ^a   Wiehle, Ronald D ^c   Bulun, Serdar E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b SHANDONG UNIVERSITY   (China)

^c Repros Therapeutics Inc   (United States)

Author keywords

antiprogestin; apoptosis; Bcl 2; myometrium; PARP; PCNA; proliferation; Uterine leiomyoma

Indexed keywords

17ALPHA ACETOXY 11BETA (4 DIMETHYLAMINOPHENYL) 21 METHOXY 19 NORPREGNA 4,9 DIENE 3,20 DIONE; CYCLINE; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 11; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYSTERECTOMY; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; SMOOTH MUSCLE FIBER; UTERUS MYOMA; WESTERN BLOTTING;

ADULT; APOPTOSIS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; FEMALE; HUMANS; LEIOMYOMA; MIDDLE AGED; MYOMETRIUM; NORPREGNADIENES; POLY(ADP-RIBOSE) POLYMERASES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, PROGESTERONE; REPRESSOR PROTEINS; UTERINE NEOPLASMS;

EID: 77952110601     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.11.031     Document Type: Article

References (36)

1. Wise L.A., Palmer J.R., Stewart E.A., and Rosenberg L. Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's Health Study. Obstet Gynecol 105 (2005) 563-568
2. Marsh E.E., and Bulun S.E. Steroid hormones and leiomyomas. Obstet Gynecol Clin North Am 33 (2006) 59-67
3. Wilcox L.S., Koonin L.M., Pokras R., Strauss L.T., Xia Z., and Peterson H.B. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 83 (1994) 549-555
4. Sankaran S., and Manyonda I.T. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol 22 (2008) 655-676
5. Cadepond F., Ulmann A., and Baulieu E.E. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 48 (1997) 129-156
6. Kloosterboer H.J., Deckers G.H., van der Heuvel M.J., and Loozen H.J. Screening of anti-progestagens by receptor studies and bioassays. J Steroid Biochem 31 (1988) 567-571
7. Neef G., Beier S., Elger W., Henderson D., and Wiechert R. New steroids with antiprogestational and antiglucocorticoid activities. Steroids 44 (1984) 349-372
8. Spitz I.M., Croxatto H.B., and Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu Rev Pharmacol Toxicol 36 (1996) 47-81
9. Teutsch G., and Philibert D. History and perspectives of antiprogestins from the chemist's point of view. Hum Reprod 9 Suppl 1 (1994) 12-31
10. Steinauer J., Pritts E.A., Jackson R., and Jacoby A.F. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 103 (2004) 1331-1336
11. Benagiano G., Bastianelli C., and Farris M. Selective progesterone receptor modulators 3: use in oncology, endocrinology and psychiatry. Expert Opin Pharmacother 9 (2008) 2487-2496
12. Levens E.D., Potlog-Nahari C., Armstrong A.Y., Wesley R., Premkumar A., Blithe D.L., et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 111 (2008) 1129-1136
13. Busso N., Collart M., Vassalli J.D., and Belin D. Antagonist effect of RU 486 on transcription of glucocorticoid-regulated genes. Exp Cell Res 173 (1987) 425-430
14. Gagne D., Pons M., and Crastes de Paulet A. Analysis of the relation between receptor binding affinity and antagonist efficacy of antiglucocorticoids. J Steroid Biochem 25 (1986) 315-322
15. Attardi B.J., Burgenson J., Hild S.A., Reel J.R., and Blye R.P. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol 188 (2002) 111-123
16. Repros Therapeutics, Inc. Available from: http://www.reprosrx.com/proellex.html[Last accessed 21 December 2009].
17. Rossi M.J., Chegini N., and Masterson B.J. Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro. Endocrinology 130 (1992) 1716-1727
18. Ishikawa H., Reierstad S., Demura M., Rademaker A.W., Kasai T., Inoue M., et al. High aromatase expression in uterine leiomyoma tissues of African-American women. J Clin Endocrinol Metab 94 (2009) 1752-1756
19. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001) 402-408
20. Yin P., Lin Z., Cheng Y.H., Marsh E.E., Utsunomiya H., Ishikawa H., et al. Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells. J Clin Endocrinol Metab 92 (2007) 4459-4466
21. Matsuo H., Maruo T., and Samoto T. Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82 (1997) 293-299
22. Klein-Hitpass L., Cato A.C., Henderson D., and Ryffel G.U. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res 19 (1991) 1227-1234
23. Spitz I.M. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 68 (2003) 981-993
24. Spitz I.M., and Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids 65 (2000) 807-815
25. Chwalisz K., Perez M.C., Demanno D., Winkel C., Schubert G., and Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrinol Rev 26 (2005) 423-438
26. Pieper A.A., Verma A., Zhang J., and Snyder S.H. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20 (1999) 171-181
27. Jang J.H., and Surh Y.J. Bcl-2 protects against Abeta(25-35)-induced oxidative PC12 cell death by potentiation of antioxidant capacity. Biochem Biophys Res Commun 320 (2004) 880-886
28. Fernandez-Zapico M.E., Mladek A., Ellenrieder V., Folch-Puy E., Miller L., and Urrutia R. An mSin3A interaction domain links the transcriptional activity of KLF11 with its role in growth regulation. EMBO J 22 (2003) 4748-4758
29. Repros Therapeutics, Inc. Available from http://www.drugs.com/clinical_trials/repros-therapeutics-inc-announces-proellex-shows-no-adverse-cardiac-pilot-trial-4237.html[Last accessed 21 December 2009].
30. Englund K., Blanck A., Gustavsson I., Lundkvist U., Sjoblom P., Norgren A., et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab 83 (1998) 4092-4096
31. Luo X., Yin P., Reierstad S., Ishikawa H., Lin Z., Pavone M.E., et al. Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. J Clin Endocrinol Metab 94 (2009) 4533-4539
32. Xu Q., Ohara N., Chen W., Liu J., Sasaki H., Morikawa A., et al. Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum Reprod 21 (2006) 2408-2416
33. Xu Q., Ohara N., Liu J., Amano M., Sitruk-Ware R., Yoshida S., et al. Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 14 (2008) 181-191
34. Morikawa A., Ohara N., Xu Q., Nakabayashi K., DeManno D.A., Chwalisz K., et al. Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. Hum Reprod 23 (2008) 944-951
35. Ohara N., Morikawa A., Chen W., Wang J., DeManno D.A., Chwalisz K., et al. Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. Reprod Sci 14 (2007) 20-27
36. Sasaki H., Ohara N., Xu Q., Wang J., DeManno D.A., Chwalisz K., et al. A novel selective progesterone receptor modulator asoprisnil activates tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated signaling pathway in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 92 (2007) 616-623